Circulation Research · 1973 · 29 citations · 21 references
HypertensionRenal InflammationCardiovascular PharmacologyPharmacotherapyMolecular PharmacologyHepatotoxicitySq 20881Resistance IncreasesHealth SciencesSodium HomeostasisAntihypertensive TherapyLiver PhysiologyVascular PharmacologyVascular BiologyRenal PathophysiologyPharmacologyPotassium HomeostasisDrug-induced Liver InjuryAngiotensin IiHepatologyCardiovascular DiseasePhysiologyMedicineAnesthesiology
The effects of angiotensin I (0.2-3.2 µg) and angiotensin II (0.1-1.6 µg) injections into the pump-perfused arterial supply of the liver were studied in dogs anesthetized with sodium pentobarbital. Marked increases in hepatic artery perfusion pressure (10-50%), reflecting directionally similar changes in resistance to blood flow, were caused by either angiotensin I or angiotensin II. Resistance increases produced by angiotensin I were significantly attenuated by the synthetic nonapeptide SQ 20881 (Pyr-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro, 50 µg/kg, iv) that inhibits enzymatic conversion of angiotensin I to angiotensin II. In contrast, responses caused by angiotensin II were unaltered by SQ 20881. However, resistance increases caused by either angiotensin I or angiotensin II were blocked by 1-Sar-8-Ala-angiotensin II (100 µg/kg min -1 , ia), a specific angiotensin II antagonist. These findings parallel the finding that responses to angiotensin I in the vasculature supplied by the hepatic artery are largely caused by local enzymatic conversion of angiotensin I to angiotensin II. Such conversion appears to occur to the extent of about 46%.
21
Conversion of Angiotensin I to Angiotensin II
K. K. F. NG, John R. Vane · Nature · 1967 · 531 citations
Fate of Angiotensin I in the Circulation
K. K. F. NG, John R. Vane · Nature · 1968 · 315 citations
Hypertension, Cardiovascular Disease, Vascular Pharmacology +5